Cogent Biosciences Inc

NASDAQ:COGTUnited States

Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Contact Information

Headquarters

275 Wyman Street, 3Rd FloorWALTHAM, MA, United States 02451

Phone

617-945-5576

Fax

---

Executives

Independent Chairman of the Board

Peter Harwin

President, Chief Executive Officer, Principal Executive Officer, Director

Andrew Robbins

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

John Green

Chief Scientific Officer

John Robinson

Chief Medical Officer

Jessica Sachs